Expression of myeloid cell leukemia-1 in diffuse large B cell lymphoma and its clinical significance
Objective:To detect the expression of Mcl-1 in diffuse large B cell lymphoma(DLBCL)and analyze the clinical significance of the expression of Mcl-1 in DLBCL.Methods:Immunohistochemical staining was used to detect the expression of Mcl-1 in paraffin pathological specimens of lymph nodes of 43 patients with DLBCL.All patients received 6-8 courses of R-CHOP regimen immunochemotherapy.According to the Lugano 2014 criteria,those who achieved CR or PR efficacy and had no relapse within 1 year were defined as the initial treatment effec-tive group(26 cases);Patients with efficacy of SD,PD,or those who had achieved CR or PR,but relapsed within 1 year were defined as the initial treatment ineffective group(17 cases).The correlation between Mcl-1 expression and clinical characteristics of DLBCL patients,as well as whether there was a difference between the treatment ef-fective group and the ineffective group was analyzed.Results:The positive rate of Mcl-1 was 58.1％,there was no correlation between the expression of Mcl-1 and the patient's gender,age and the presence or absence of symptoms of B etc(P＞0.05).After the initial immunochemotherapy,the positive rate of Mcl1 was 38.5％(10/26)in the effective group and 88.2％(15/17)in the ineffective group(P＜0.05).The probability that the group of positive Mcl-1 expression had no response to the initial immunochemotherapy was 15.625 times that of the negative group,the hypothesis that Bcl-2 expression was a predictor of therapeutic response was not valid.The effect of the com-bined prediction model of Mcl-1 and Bcl-2 was better than that of the single prediction model of Mcl-1 or Bcl-2.Conclusion:The expression of Mcl-1 could be used as a predictor of DLBCL's no response to initial immunochemo-therapy.As an independent factor of poor prognosis,coexpression of Bcl-2 and Mcl-1 could be a rational choice.
diffuse large B cell lymphomaBcl-2Mcl-1targeted therapyinhibitors
NETL
NSTL
万方数据
